Two Oncologics Face Tough ODAC Review: Problems Of Efficacy For Schering's PegIntron And Safety For GSK's Votrient

01 Oct 2009

• By The Pink Sheet Daily

The Oncologic Drugs Advisory Committee will meet Oct. 5 to evaluate the sNDA for PegIntron to treat melanoma and the NDA for Votrient to treat renal cell carcinoma.

Two Oncologics Face Tough ODAC Review: Problems Of Efficacy For Schering's PegIntron And Safety For GSK's Votrient

More from Archive

More from Pink Sheet